Heidi Bruty, MD
Child, Adolescent and Adult Psychiatric Medicine
Previous Employment
Assistant Professor
UT Southwestern Medical School
Department of Child and Adolescent Psychiatry
July 2010 – June 2014
Center for Pediatric Eating Disorders
Children's Medical Center @ Legacy, Plano, Texas
November 2013 - June 2014
Medical Director, Inpatient Psychiatry
Children's Medical Center, Dallas, Texas
November 2011 - November 2013
Assistant Medical Director, Psychiatry Consult Liason
Children’s Medical Center, Dallas, Texas
July 2010 – November 2011
Staff Child & Adolescent Psychiatrist
Dallas Metrocare Services, Dallas Texas
July 2009 – July 2010
Assistant Professor
University of South Florida College of Medicine
Department of Psychiatry and Behavioral Medicine
Division, Child and Adolescent Psychiatry
February 2007 – November 2008
Child & Adolescent Psychiatry Fellowship
Department of Psychiatry and Behavioral Medicine
University of South Florida College of Medicine
Tampa, Florida
September 2004-November 2006
General Adult Psychiatry Residency
Department of Psychiatry and Behavioral Medicine
University of South Florida College of Medicine
Tampa, Florida
July 2001- September 2004
Medical Education
Doctor of Medicine
University of South Florida College of Medicine
Tampa, Florida
1997-2001
Graduate Education
Post-Baccalaureate Studies
University of South Florida
Tampa, Florida
1996-1997
Undergraduate Education
Bachelor of Arts
Graduated Phi Beta Kappa
Emory University
Atlanta, Georgia
1992-1996
Certifications
Diplomate of Board of Child & Adolescent Psychiatry, re-certified April 2017
Diplomate of Board of Psychiatry and Neurology, re-certified April 2017
Honors and Awards
- Chief Resident, Child and Adolescent Psychiatry, 2005-2006
- Ginsberg Fellowship with Group for the Advancement of Psychiatry, 2002-2004
- AACAP Eli Lilly Outstanding General Psychiatry Resident Award,2002
- University of South Florida, Department of Psychiatry and Behavioral Medicine, Chairman's Award for Scholarly and Creative Activity, 2002
- Outstanding Student in Psychiatry, University of South Florida College of Medicine, 2000-2001
- Award for Clinical Excellence in Psychiatry Clerkship, University of South Florida College of Medicine, 1999-2000
- Magna Cum Laude, Emory University, 1996
- Phi Beta Kappa, Emory University, 1995
Publications
- Bruty HR, Emslie GJ, Croarkin P. Novel (Atypical) Antidepressants. Pharmacotherapy of Child and Adolescent Psychiatric Disorders, Third Edition. Rosenberg D and Gershon S (eds). John Wiley & Sons, Ltd., 2012
- Power P, Bruty, H: Pharmacotherapy for Eating Disorders and Obesity, Child and Adolescent Psychiatric Clinics of North America, 2008;18: 31-47
- Berman EM, Heru AM, Grunebaum H, Rolland J, Wood B, Bruty H: Family Skills for General Psychiatry Residents: Meeting ACGME Core Competency Requirements, Academic Psychiatry, 2006; 30(1): 69-78
- Brauer HR, Nowicki PW, Catalano G, Catalano MC: Panic Attacks Associated with Citalopram, Southern Medical Journal, 2002; 95(9): 1088-1089
- Smith AG, Brauer HR, Catalano G, Catalano MC: Topiramate Overdose: A Case Report and Literature Review, Epilepsy & Behavior, 2001; 2: 603-607
Research Activities
- Sub-Investigator, Forest, “Open Label Long-Term Study of Escitalopram in Children 7 to 11 Years of Age with Major Depressive Disorder (SCT MD 55), 2011
- Principal Investigator, GlaxoSmithKline, “The Evaluation of LAMCITAL as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10-17 Years of Age (SCA 102833), 2008
- Principal Investigator, Boehringer Ingelheim, "An open-label, flexible dose, follow-up study to evaluate safety and efficacy of oral Pramipexole (0.0625-0.5 mg/day) for 24 weeks in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette's Disorder according to DSM-IV criteria and who have completed the double-blind phase of either study 248.641 or 248.644,"2008
- Principal Investigator, Boehringer Ingelheim, "A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.125-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-17 inclusive) diagnosed with Tourette's Disorder according to DSM-IV criteria," 2008
- Sub-Investigator, Bristol Myers Squibb, “Multicenter, ouble-Blind,Randomized, Placebo-Controlled, Parallel-Group Study with Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents with Autism Disorder,” 2007-2008
- Sub-Investigator, Bristol Myers Squibb, “A 52 Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder,” 2007-2008
Professional Memberships
- American Psychiatric Association
- American Academy of Child and Adolescent Psychiatry
- American Medical Association
Printable Version